On June 4, Thermo Fisher Scientific rose 3.05% in regular trading, trading at $488.15/share, with trading volume of $262 million. The stock recovered losses from the prior session as the life sciences tools and services sector staged a broad rebound.

On the news front, the AI-empowered life sciences theme continued to gain traction following OpenAI's recent launch of GPT-Rosalind, a model focused on life sciences research, developed in collaboration with Thermo Fisher to be integrated across various workflows. The sector saw strong collective gains, with Tempus AI surging 12.13%, Danaher rising 5.16%, IQVIA up 3.28%, and Illumina gaining 3.31%, demonstrating significant sector linkage effects.

Notably, the rebound came despite HSBC downgrading Thermo Fisher from buy to hold and cutting its price target from $670 to $540. Analyst consensus still maintains an average buy rating with a mean price target of $602.50. The company reported Q1 revenue of $11.01 billion with adjusted EPS of $5.44, both exceeding expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)